分化型甲状腺癌血液标志物的研究现状及进展被引量：7

Blood biomarkers in differentiated thyroid cancer:current status and advances

导出

摘要目的阐述近年来有关分化型甲状腺癌的血液标志物的研究现状及进展,以提高分化型甲状腺癌的临床诊治水平。方法对近年来国内外有关分化型甲状腺癌的血液标志物、液体活检等文献进行检索,对不同标志物进行归纳总结与分析。结果甲状腺球蛋白和甲状腺球蛋白抗体是分化型甲状腺癌目前最常用的血清学标志物,微小RNA、长链非编码RNA等血液标志物在分化型甲状腺癌的诊断、治疗和随访中的应用价值也不断被发现。结论因血液标志物具有特异度高、敏感度强且无创等优点,是未来协助提高甲状腺癌患者的诊断准确率、监测患者疾病进展及复发的有用指标。 Objective In order to improve the levels of clinical diagnosis and treatment of differentiated thyroid cancer, the research status and progress of blood markers of differentiated thyroid cancer in recent years were reviewed. Method The literatures about blood markers and liquid biopsy of differentiated thyroid cancer at home and abroad in recent years were searched and summarized. Results Thyroglobulin and thyroglobulin antibody were the most commonly used for markers of differentiated thyroid cancer. The application value of blood markers such as microRNA and long non-coding RNA in the diagnosis, treatment and follow-up of differentiated thyroid cancer had also been found. Conclusion Because of the advantages of high specificity, high sensitivity, and no-invasion, blood markers are useful indicators to help improve the diagnosis of thyroid cancer patients and monitor the disease progression and recurrence in the future.

作者高旭喻庆安闫肖代文杰 GAO Xu;YU Qing’an;YAN Xiao;DAI Wenjie(Department of Thyroid Surgery,The First Affiliated Hospital,Harbin Medical University,Harbin 150001,P.R.China)

机构地区哈尔滨医科大学附属第一医院甲状腺外科

出处《中国普外基础与临床杂志》 CAS 2022年第1期118-123,共6页 Chinese Journal of Bases and Clinics In General Surgery

关键词分化型甲状腺癌血液标志物甲状腺球蛋白液体活检 differentiated thyroid cancer blood marker thyroglobulin liquid biospy

分类号 R736.1 [医药卫生—肿瘤]

引文网络
相关文献

参考文献1

1孟召伟,谭建,张桂芝,李宁,田伟军,付强,何向辉,李卫东,张卿.血清midkine测定在分化型甲状腺癌诊断和预后评价中的价值[J].中华核医学与分子影像杂志,2015,35(3):177-181. 被引量：9

二级参考文献15

1Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[ J]. CA Cancer J Clin, 2014, 64( 1): 9-29.
2American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer [ J ]. Thyroid, 2009, 19(11): 1167-1214.
3Muramatsu T, Kadomatsu K. Midkine: an emerging target of drug development for treatment of multiple diseases[ J]. Br J Pharmacol, 2014, 171(4): 811-813.
4Muramatsu T. Structure and function of midkine as the basis of its pharmacological effects[J]. BrJ Pharmaeol, 2014, 171(4): 814- 826.
5Zhu WW, Guo JJ, Guo L, et al. Evaluation of midkine as a diagnos- tic serum biomarker in hepatocellular carcinoma [ J ]. Clin Cancer Res, 2013, 19(14) : 3944-3954.
6Lucas S, Reindl T, Henze G, et al. Increased midkine serum lev- els in pediatric embryonal tumor patients [ J ]. J Pediatr Hematol Oneol, 2009, 31(10): 713-717.
7Shimada H, Nabeya Y, Tagawa M, et al. Preoperative serum mid- kine concentration is a prognostic marker for esophageal squamous cell carcinoma [ J]. Cancer Sei, 2003, 94(7): 628-632.
8Ota K, Fujimori H, Ueda M, et al. Midkine as a prognostic bio- marker in oral squamous cell carcinoma [ J ]. Br J Cancer, 2008, 99(4) : 655-662.
9Rawnaq T, Kunkel M, Baehmann K, et al. Serum midkine corre- lates with tumor progression and imatinib response in gastrointesti- nal stromal tumors[ J]. Ann Surg Oncol, 2011, 18(2) : 559-565.
10Jones DR. Measuring midkine : the utility of midkine as a biomarker in cancer and other diseases [J]. Br J Pharmaeol, 2014, 171 (12) : 2925-2939.